Scholarlink

<p>Statins are marketed as antihyperlipidemic drugs, have been repurposed in cancer management. Their repurposing is based on antiproliferative, apoptotic, and anti-metastatic properties. Head and neck cancer, including oral carcinoma, remains a global burden with limited advancements. Therefore, we study the preclinical and clinical advancements of statins and statins-loaded nanocarriers in head and neck cancer. Data were extracted from various sources, including PubMed, Scopus, and Web of Science. Publications reporting in vitro, in vivo, and clinical data were evaluated. Data will be extracted and assessed following PRISMA guidelines. Various statistical parameters, such as Risk Ratio and Odds Ratio, were computed to analyze the reported clinical trials. This systematic review provides evidence-based proof of the anticancer potential of statins. Research gaps and future perspectives have also been discussed.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Repurposing statins for the management of head and neck squamous cell carcinoma: A systematic review of preclinical and clinical evidence

  • 期刊论文

  • 发表日期：

    2026年6月17日

查看全文
  • Paras Famta,
  • Ganesh Vambhurkar,
  • Giriraj Pandey,
  • Suraj Wagh,
  • Abhishek Sharma,
  • Chandan Pandia,
  • Bishal Samadder,
  • Saurabh Srivastava

摘要

Statins are marketed as antihyperlipidemic drugs, have been repurposed in cancer management. Their repurposing is based on antiproliferative, apoptotic, and anti-metastatic properties. Head and neck cancer, including oral carcinoma, remains a global burden with limited advancements. Therefore, we study the preclinical and clinical advancements of statins and statins-loaded nanocarriers in head and neck cancer. Data were extracted from various sources, including PubMed, Scopus, and Web of Science. Publications reporting in vitro, in vivo, and clinical data were evaluated. Data will be extracted and assessed following PRISMA guidelines. Various statistical parameters, such as Risk Ratio and Odds Ratio, were computed to analyze the reported clinical trials. This systematic review provides evidence-based proof of the anticancer potential of statins. Research gaps and future perspectives have also been discussed.

Graphical Abstract